Ocugen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
For members of the inherited retinal disease (IRD) community, corporate updates from clinical-stage biotechnology companies offer a window into the ongoing development of potential new therapies. Ocugen, Inc. recently published its financial results for the fourth quarter and full year 2025, alongside a comprehensive business overview detailing the progress of its modifier gene therapy programs.
According to Ocugen, the company reported research and development expenses of $10.7 million for the fourth quarter of 2025, up from $8.3 million during the same period in 2024. For the full year ended December 31, 2025, research and development expenses reached $39.8 million, compared to $32.1 million in 2024. The company noted a net loss per common share of $0.06 for the fourth quarter and $0.23 for the full year 2025. Cash and restricted cash stood at $18.9 million as of December 31, 2025. To support ongoing operational needs, Ocugen secured $22.5 million in gross proceeds through a January 2026 financing round.
Beyond the financial figures, the company provided updates on its clinical pipeline targeting retinal and blindness diseases. Ocugen reported that enrollment was completed for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa. Additionally, the company highlighted progress regarding OCU410ST for Stargardt disease and OCU410 for geographic atrophy secondary to dry age-related macular degeneration.
For patients and families navigating rare retinal conditions, these pipeline updates reflect the continuous operational steps required to advance clinical trials toward potential regulatory milestones. Financial disclosures and clinical trial statuses help the community track the progress of emerging genetic and modifier therapies.
Ocugen stated that it will continue advancing its clinical programs and monitoring financial runways as its pipeline trials proceed through their respective phases.